Please note: The information displayed on this page might be outdated.
Arvelle Therapeutics: Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received start-up financing of $207.8 million, one of the largest initial financing commitments for a European-focused biopharmaceutical company, with investments from a global syndicate including NovaQuest Capital Management, BRV Capital Management, LSP, H.I.G. BioHealth Partners, Andera Partners, F-Prime Capital and KB Investments.
Phase III, Phase l or ll
Central Nervous System, Rare Disease
100MM - 500MM
Company Participants at Fall Private Company Showcase 2020
Arvelle Therapeutics, CFO & CBO
Gregory Weinhoff, MD is a Founder, Board Member and Chief Financial Officer and Chief Business Officer. He previously served as Chief Financial Officer of Axovant Sciences. He has more than 20 years of experience in healthcare finance and operations as a venture capital investor and operating executive. Previously, Dr. Weinhoff was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across biotechnology, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently served on the company’s board of directors. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.
Arvelle Therapeutics, CEO
Mr. Altmeyer is a Founder, Board Member and the Chief Executive Officer of Arvelle. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system (CNS) disorders. He was previously President and Chief Commercial Officer at Axovant. Prior to that Mark was Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led a team of 1,700 employees and helped grow the company’s revenue from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit. Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.